http://www.fpnotebook.com/
Protease Inhibitor
Aka: Protease Inhibitor
- See Also
- Anti-Retroviral Therapy
- Mechanism
- Prevent HIV from being assembled
- Prevent release from infected CD4 cells
- Protocols
- Most Protease Inhibitors are "boosted" with concurrent use of Ritonavir (Norvir)
- Limited by adverse gastrointestinal effects
- Preparations- suffix '/r' added when combined with Ritonavir
- Amprenavir (Agenerase)
- Atazanavir (Reyataz, ATV or ATV/r)
- Unboosted (without Ritonavir) has least adverse effect on lipids
- Darunavir (DRV or DRV/r)
- Less adverse effects on lipid profile
- Fosamprenavir (Lexiva, FPV or FPV/r)
- Indinavir (Crixivan)
- Lopinavir with Ritonavir (Kaletra, LPV/r)
- Nelfinavir (Viracept)
- Ritonavir (Norvir, /r)
- Saquinavir (Fortovase)
- Saquinavir mesylate (Invirase)
- Tipranavir (Aptivus)
- Precautions
- Saquinavir and Saquinavir mesylate are not equivalent
- Adverse Effects
- See each individual agent for specific adverse effects
- Nephrolithiasis (Indinavir)
- Severe Diarrhea (Nelfinavir)
- Gastrointestinal upset
- Lipodystrophy
- Insulin Resistance
- Manage with lifestyle changes (diet, Exercise)
- Consider medications
- Thiazolidinediones (eg Rosiglitazone, Pioglitazone)
- Glucophage
- Severe lipid abnormalities
- Effects
- Hypertriglyceridemia
- Low HDL
- Management
- Consider Atazanavir (unboosted or boosted) or boosted Darunavir (DRV)
- Can be treated with Pravastatin (see below)
- Resolves with discontinuation of Protease Inhibitor
- Hepatotoxicity
- Associated with concurrent use of other HIV agents
- Associated with comorbid Hepatitis C
- Osteopenia
- Drug Interactions
- Drug interactions are common
- Protease Inhibitors cause the most drug interactions of all Antiretrovirals
- Statin drugs (used for PI-induced lipid abnormalities)
- Pravastatin is first choice Statin for use with PI
- Rosuvastatin (Crestor) or Atorvastatin (Lipitor) may also be used with caution
- Do not use Simvastatin or Lovastatin with PI
- Monitoring
- Fasting lipid panel with Glucose every 3-6 months
- References
- (1998) Med Lett Drugs Ther 40(1041):115
- (2009) Treat Guidel Med Lett 7(78): 11-22
- Reust (2011) Am Fam Physician 83(12): 1443-51